CDKN2A and Miyoshi myopathy: Of note, the importance of the p16 status for the diagnosis of MM was recently confirmed by Nabeshima and colleagues [2], while further studies to validate its role as a predictor of prognosis and response/resistance to treatment in patients with MM and other solid tumours are underway [7].